Literature DB >> 30792487

Characteristics of β-oxidative and reductive metabolism on the acyl side chain of cinnamic acid and its analogues in rats.

Kai-Jing Zhao1, Yang Chen1, Shi-Jin Hong1, Yi-Ting Yang1, Jiong Xu1, Han-Yu Yang1, Liang Zhu1, Ming Liu1, Qiu-Shi Xie1, Xian-Ge Tang1, Ting-Ting Yang1, Ya-Qian Zhou1, Li Liu2, Xiao-Dong Liu3.   

Abstract

Cinnamic acid and its analogues (pyragrel and ozagrel) undergo chain-shortened (β-oxidative) and reductive metabolism on acyl side chain. In this study, we characterized the β-oxidative and reductive metabolism on acyl side chain of cinnamic acid and its analogues using primary rat hepatocytes, hepatic mitochondrial, and microsomal systems. A compartmental model including parent compounds and metabolites was developed to characterize in vivo β-oxidative and reductive metabolism following an intravenous dose of parent compounds to rats. The fitted total in vivo clearance values were further compared with the in vitro values predicted by the well-stirred model. We showed that hepatic microsomal CYP450s did not catalyze β-oxidative or reductive metabolism of the three compounds. Similar to β-oxidation of fatty acids, β-oxidative metabolism on their acyl side chain occurred mainly in mitochondria, which was highly dependent on ATP, CoA and NAD+. Fatty acids and NADH inhibited the β-oxidative metabolism. Reductive metabolism occurred in both mitochondria and microsomes. Reduction in mitochondria was ATP-, CoA-, and NAD(P)H-dependent and reversible, which was suppressed by enoyl reductase inhibitor triclosan. Reduction in microsomes was ATP-, CoA-, and NADPH-dependent but little affected by triclosan. Both plasma concentrations of β-oxidative metabolites and reductive metabolites were successfully fitted using the compartmental model. The estimated total in vivo clearance values were consistent with those predicted from hepatocytes and organelles, implicating significance of in vitro kinetics. These findings demonstrate the roles of hepatic mitochondria and microsomes in β-oxidative and reductive metabolism on acyl side chain of cinnamic acid and its analogues along with their metabolic characteristics.

Entities:  

Keywords:  antiplatelet drug; cinnamic acid; drug metabolism; hepatocytes; in vitro-in vivo correlation; microsomes; mitochondria; ozagrel; pharmacokinetics; pyragrel

Mesh:

Substances:

Year:  2019        PMID: 30792487      PMCID: PMC6786313          DOI: 10.1038/s41401-019-0218-8

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  45 in total

1.  Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations.

Authors:  T Ogiso; M Iwaki; Y Hara; T Tanino
Journal:  J Pharm Sci       Date:  1997-10       Impact factor: 3.534

2.  Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke.

Authors:  Hiroaki Oguro; Shingo Mitaki; Hiroyuki Takayoshi; Satoshi Abe; Keiichi Onoda; Shuhei Yamaguchi
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-04-26       Impact factor: 2.136

3.  Simultaneous determination of Pyragrel, a novel anti-thrombotic agent, and its two primary metabolites in plasma by HPLC-MS/MS.

Authors:  Guoping Yang; Qi Pei; Chengxiao Fu; Jie Huang; Jun Chen; Shuang Yang; Yuxia Xiang; Jing Wang; Hongyi Tan; Xiaolei Liu
Journal:  J Pharm Biomed Anal       Date:  2018-04-14       Impact factor: 3.935

Review 4.  Mechanisms and physiological roles of fatty acid chain elongation in microsomes and mitochondria.

Authors:  W Seubert; E R Podack
Journal:  Mol Cell Biochem       Date:  1973-05-11       Impact factor: 3.396

5.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.

Authors:  Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

6.  MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition.

Authors:  Weirong Fang; Jie Wei; Dan Han; Xi Chen; Guangwei He; Qiang Wu; Shaoxing Chu; Yunman Li
Journal:  Thromb Res       Date:  2014-01-29       Impact factor: 3.944

7.  The metabolism of phenolic acids in the rat.

Authors:  S Ranganathan; T Ramasarma
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

8.  Metabolism of trans-cinnamic acid in the rat and the mouse and its variation with dose.

Authors:  B P Nutley; P Farmer; J Caldwell
Journal:  Food Chem Toxicol       Date:  1994-10       Impact factor: 6.023

Review 9.  The occurrence, metabolism and toxicity of cinnamic acid and related compounds.

Authors:  J A Hoskins
Journal:  J Appl Toxicol       Date:  1984-12       Impact factor: 3.446

10.  Profiling and Preparation of Metabolites from Pyragrel in Human Urine by Online Solid-Phase Extraction Coupled with High Performance Liquid Chromatography Tandem Mass Spectrometry Followed by a Macroporous Resin-Based Purification Approach.

Authors:  Xin Zhao; Jingjing Jiang; Guang Yang; Jie Huang; Guoping Yang; Guangwei He; Zhaoxing Chu; Taijun Hang; Guorong Fan
Journal:  Molecules       Date:  2017-03-21       Impact factor: 4.411

View more
  1 in total

Review 1.  Sodium Benzoate-Harmfulness and Potential Use in Therapies for Disorders Related to the Nervous System: A Review.

Authors:  Łucja Justyna Walczak-Nowicka; Mariola Herbet
Journal:  Nutrients       Date:  2022-04-02       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.